Drug-Induced Hyperglycaemia and Diabetes

Drug Safety

Volumn 38, Issue 12, 2015, Pages 1153-1168

  Fathallah, Neila ^a   Slim, Raoudha ^a   Larif, Sofien ^a   Hmouda, Houssem ^b   Ben Salem, Chaker ^a  

^a Department of Pharmacovigilance ^*  (Tunisia)

^b SAHLOUL UNIVERSITY HOSPITAL   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIMYCOBACTERIAL AGENT; ANTINEOPLASTIC AGENT; ANTIPROTOZOAL AGENT; ANTIVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIAZOXIDE; GLUCOCORTICOID; GLUCOSE; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; NEUROLEPTIC AGENT; NICOTINIC ACID; ORAL CONTRACEPTIVE AGENT; SOMATOSTATIN DERIVATIVE; THIAZIDE DIURETIC AGENT; DRUG; INSULIN;

CYTOTOXICITY; DIABETES MELLITUS; DRUG INDUCED DISEASE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; KETOACIDOSIS; PANCREAS CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; ADVERSE DRUG REACTION; CHEMICALLY INDUCED; CLASSIFICATION; METABOLISM;

DIABETES MELLITUS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; HYPERGLYCEMIA; INSULIN; PHARMACEUTICAL PREPARATIONS;

EID: 84948574437     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0339-z     Document Type: Review

References (186)

1. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2015;38(Suppl):S8–16.
2. Liu XX, Zhu XM, Miao Q, Ye HY, Zhang ZY, Li YM. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Ann Nutr Metab. 2014;65(4):324–32.
3. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant. 2004;4:583–95.
4. Luna B, Feinglos MN. Drug-induced hyperglycemia. JAMA. 2001;286(16):1945–8.
5. Chan JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism: mechanisms and management. Drug Saf. 1996;15(2):135–57.
6. Pandit MK, Burke J, Gustafson AB, Minocha A, Peiris AN. Drug-induced disorders of glucose tolerance. Ann Intern Med. 1993;118(7):529–39.
7. Ferner RE. Drug-induced diabetes. Baillieres Clin Endocrinol Metab. 1992;6(4):849–66.
8. Chan JC, Cockram CS. Drug-induced disturbances of carbohydrate metabolism. Adverse Drug React Toxicol Rev. 1991;10(1):1–29.
9. Springer Link. Reactions Weekly. http://link.springer.com/journal/40278. Accessed 24 Aug 2015.
10. Dunder K, Lind L, Zethelius B, Berglund L, Lithell H. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. BMJ. 2003;326:681.
11. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963–9.
12. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995–1003.
13. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin–angiotensin system reduces the incidence of new-onset diabetes. J Hypertens. 2005;23:463–73.
14. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet. 1981;2:539–543.
15. Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR, et al. Influence of long-term, low dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med. 1998;158:741–51.
16. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366–72.
17. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.
18. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network metaanalysis. Meta-analysis of clinical trials showing of all antihypertensives analyzed, β-blockers and thiazide diuretics are associated with the highest risk of diabetes. Lancet. 2007;369(9557):201–7.
19. Alderman MH. New onset diabetes during antihypertensive therapy. Am J Hypertens. 2008;21(5):493–9.
20. Hirst JA, Farmer AJ, Feakins BG, Aronson JK, Stevens RJ. Quantifying the effects of diuretics and beta-blockers on glycaemic control in diabetes mellitus—a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;79(5):733–43.
21. Duarte JD, Cooper-DeHoff RM. Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther. 2010;8(6):793–802.
22. Ben Salem C, Hmouda H, Bouraoui K. Drug-induced hypokalaemia. Curr Drug Saf. 2009;4(1):55–61.
23. Tourniaire J, Bajard L, Harfouch M, Rebattu B, Garrel D. Restoration of insulin sensitivity after correction of hypokalemia due to chronic tubulopathy in a diabetic patient. Diabete Metab. 1988;14(6):717–20.
24. Ayvaz G, Balos Törüner F, Karakoç A, Yetkin I, Cakir N, Arslan M. Acute and chronic effects of different concentrations of free fatty acids on the insulin secreting function of islets. Diabetes Metab. 2002;28:3S7–12.
25. Eriksson JW, Jansson PA, Carlberg B, Hägg A, Kurland L, Svensson MK, et al. Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the Mechanisms For the Diabetes Preventing Effect of Candesartan (MEDICA) study. Hypertension. 2008;52(6):1030–7.
26. Fernandez PG, Snedden W, Vasdev S, Bolli P. Bevantolol attenuates thiazide stimulated renin secretion and catecholamine release in diuretic resistant hypertensives. Can J Cardiol. 1989;5(2):93–7.
27. Messerli FH, Bangalore S, Yao SS, Steinberg JS. Cardioprotection with beta-blockers: myths, facts and Pascal’s wager. J Intern Med. 2009;266(3):232–41.
28. Shen L, Shah BR, Reyes EM, Thomas L, Wojdyla D, Diem P, et al. Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ. 2013;347.
29. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000;342:905–12.
30. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95:29–35.
31. Rizos CV, Elisaf MS. Antihypertensive drugs and glucose metabolism. World J Cardiol. 2014. 26;6(7):517–530.
32. Samuelsson O, Hedner T, Berglund G, Persson B, Andersson OK, Wilhelmsen L. Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the Primary Prevention Trial Goteborg, Sweden. J Hum Hypertens. 1994;8:257–63.
33. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007;100(8):1254–62.
34. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the Carvedilol–Metoprolol Study. J Hypertens. 1996;14:489–94.
35. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292(18):2227–36.
36. Rosei EA, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoreceptor antagonist with unique characteristics. Drugs. 2007;67:1097–107.
37. ++ in glucose-stimulated biphasic insulin release by rat islets. J Clin Investig. 1978;62(2):451–8.
38. Amorim S, Dias P, Rocha G, Gama G, de Campos M, Pires S. Poisoning with calcium channel blockers—a case report and review of the literature. Rev Port Cardiol. 2001;20(12):1249–57.
39. Noto H, Goto A, Tsujimoto T, Noda M. Effect of calcium channel blockers on incidence of diabetes: a meta-analysis. Diabetes Metab Syndr Obes. 2013;6:257–61.
40. Ahmad S. Nicardipine-induced hyperglycemia. Am Fam Physician. 1992;45(2):449–52.
41. Sharma SN, Iyengar SS, Hegde KP. Nifedipine induced hyperglycaemia. J Assoc Physicians India. 1990;38(9):673–4.
42. Levine M, Boyer EW, Pozner CN, Geib AJ, Thomsen T, Mick N, et al. Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil. Crit Care Med. 2007;35(9):2071–5.
43. Salerno DM, Fifield J, Krejci J, Hodges M. Encainide-induced hyperglycemia. Am J Med. 1988;84(1):39–44.
44. Winter WE, Funahashi M, Koons J. Encainide-induced diabetes: analysis of islet cell function. Res Commun Chem Pathol Pharmacol. 1992;76(3):259–68.
45. Politi A, Poggio G, Margiotta A. Can amiodarone induce hyperglycaemia and hypertriglyceridaemia? Br Med J. 1984;288:285.
46. Yildirim SV, Azak E, Varan B, Tokel K. Unusual and early hyperglycemia following amiodarone infusion in two infants. Pediatr Cardiol. 2005;26(5):715–6.
47. Bang CN, Okin PM. Statin treatment, new-onset diabetes, and other adverse effects: a systematic review. Curr Cardiol Rep. 2014;16(3):461.
48. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009;32:1924–9.
49. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.
50. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623–30.
51. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–57.
52. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–58.
53. Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, Wun CC, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol. 2011;57:1535–45.
54. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:357–62.
55. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565–71.
56. Ray K. Statin diabetogenicity: guidance for clinicians. Cardiovasc Diabetol. 2013;12:S3.
57. Chan DC, Pang J, Watts GF. Pathogenesis and management of the diabetogenic effect of statins: a role for adiponectin and coenzyme q10? Curr Atheroscler Rep. 2015;17(1):472.
58. Pieper JA. Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. Am J Health Syst Pharm. 2003;60:S9–14.
59. Molnar GD, Berge KG, Rosevear JW, McGuckin WF, Achor RW. The effect of nicotinic acid in diabetes mellitus. Metabolism. 1964;13:181–90.
60. Chang AM, Smith MJ, Galecki AT, Bloem CJ, Halter JB. Impaired beta-cell function in human aging: response to nicotinic acid-induced insulin resistance. J Clin Endocrinol Metab. 2006;91(9):3303–9.
61. Koh Y, Bidstrup H, Nichols DL. Niacin increased glucose, insulin, and C-peptide levels in sedentary nondiabetic postmenopausal women. Int J Womens Health. 2014;6:913–20.
62. Kahn SE, Beard JC, Schwartz MW, Ward WK, Ding HL, Bergman RN, et al. Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes. 1989;38(5):562–8.
63. Mariot P, Gilon P, Nenquin M, Henquin JC. Tolbutamide and diazoxide influence insulin secretion by changing the concentration but not the action of cytoplasmic Ca2+inβ-cells. Diabetes. 1998;47:365–73.
64. Gill GV, Rauf O, MacFarlane IA. Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J. 1997;73:640–1.
65. Catero M. Dysglycemia and fluoroquinolones: are you putting patients at risk? J Fam Pract. 2007;56(2):101–7.
66. Anderson VR, Perry CM. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs. 2008;68(4):535–65.
67. Liu HH. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf. 2010;33(5):353–69.
68. Yip C, Lee AJ. Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature. Clin Ther. 2006;28(11):1857–66.
69. Ben Salem C, Fathallah N, Hmouda H, Bouraoui K. Drug-induced hypoglycaemia: an update. Drug Saf. 2011;34(1):21–45.
70. Pugi A, Longo L, Bartoloni A, Rossolini GM, Mugelli A, Vannacci A, et al. Cardiovascular and metabolic safety profiles of the fluoroquinolones. Expert Opin Drug Saf. 2012;11(1):53–69.
71. Ovartlarnporn M, Jongjaroenprasert W. Advancing age and renal impairment as important predisposing factors of gatifloxacin-induced hyperglycemia in non-diabetes patients. J Med Assoc Thai. 2007;90:569–73.
72. Aspinall SL, Good CB, Jiang R, McCarren M, Dong D, Cunningham FE. Severe dysglycemia with the fluoroquinolones: a class effect? Clin Infect Dis. 2009;49(3):402–8.
73. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med. 2006;354:1352–61.
74. Manish G, Keshav GK, Syed RM, Sukriti K, Abhinav G. Isoniazid induced childhood diabetes: a rare phenomenon. J Basic Clin Pharm. 2015;6(2):74–6.
75. Takasu N, Yamada T, Miura H, Sakamoto S, Korenaga M, Nakajima K, et al. Rifampicin-induced early phase hyperglycemia in humans. Am Rev Respir Dis. 1982;125(1):23–7.
76. Hardy H, Esch LD, Morse GD. Glucose disorders associated with HIV and its drug therapy. Ann Pharmacother. 2001;35(3):343–51.
77. Albrecht H, Stellbrink HJ, Arastéh K. Didanosine-induced disorders of glucose tolerance. Ann Intern Med. 1993;119(10):1050.
78. Modest GA, Fuller J. Abacavir and diabetes. N Engl J Med. 2001;344(2):142–4.
79. Reus S, Arroyo E, Boix V, Portilla J. Lipodystrophy and hyperglycemia produced by protease inhibitors. An Med Interna. 2000;17(3):123–6.
80. Gómez-Vera J, de Alarcón A, Jiménez-Mejías ME, Acosta D, Prados D, Viciana P. Hyperglycemia associated with protease inhibitors in HIV-1-infected patients. Clin Microbiol Infect. 2000;6:391–4.
81. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353(9170):2093–9.
82. Dubé MP, Edmondson-Melançon H, Qian D, Aqeel R, Johnson D, Buchanan TA. Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients. J Acquir Immune Defic Syndr. 2001;27(2):130–4.
83. Vyas AK, Koster JC, Tzekov A, Hruz PW. Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice. J Biol Chem. 2010;285(47):36395–400.
84. Johnston SS, Juday T, Esker S, Espindle D, Chu BC, Hebden T, et al. Comparative incidence and health care costs of medically attended adverse effects among US Medicaid HIV patients on atazanavir- or darunavir-based antiretroviral therapy. Value Health. 2013;16(2):418–25.
85. Kulkarni R, Kinikar A. Transient hyperglycemia in a H1N1 positive child on oseltamivir. Indian Pediatr. 2010;47(9):812–3.
86. Liegl U, Bogner JR, Goebel FD. Insulin-dependent diabetes mellitus following pentamidine therapy in a patient with AIDS. Clin Investig. 1994;72:1027–9.
87. Coyle P, Carr AD, Depczynski BB, Chisholm DJ. Diabetes mellitus associated with pentamidine use in HIV-infected patients. Med J Aust. 1996;165:587–8.
88. Shen M, Orwoll ES, Conte JE Jr, Prince MJ. Pentamidine-induced pancreatic beta-cell dysfunction. Am J Med. 1989;86:726–8.
89. Fariss BL, Lutcher CL. Diphenylhdantoin-induced hyperglycemia and impaired insulin release: effect of dosage. Diabetes. 1971;20(3):177–81.
90. Al-Rubeaan K, Ryan EA. Phenytoin-induced insulin insensitivity. Diabet Med. 1991;8:968–70.
91. Hurel SJ, Taylor R. Drugs and glucose tolerance. Advers Drug React Bull. 1995;174:659–62.
92. Verrotti A, Manco R, Agostinelli S, Coppola G, Chiarelli F. The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia. 2010;51:268–73.
93. Fertig MK, Brooks VG, Shelton PS, English CW. Hyperglycemia associated with olanzapine. J Clin Psychiatry. 1998;59:687–9.
94. Avella J, Wetli CV, Wilson JC, Katz M, Hahn T. Fatal olanzapine-induced hyperglycemic ketoacidosis. Am J Forensic Med Pathol. 2004;25:172–5.
95. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000;157:975–81.
96. Nakamura M, Nagamine T. Severe hyperglycemia induced by olanzapine was improved with a recovery of insulin secretion after switching to risperidone and introducing insulin therapy. Intern Med. 2010;49:2635–7.
97. Isaac MT, Isaac MB. Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. Diabetes Care. 2004;27:2088.
98. Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004;65:4–18.
99. Lean ME, Pajonk FG. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care. 2003;26(5):1597–605.
100. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002;22:841–52.
101. Létourneau G, Abdel-Baki A, Dubreucq S, Mahone M, Granger B. Hyperosmolar hyperglycemic state associated with ziprasidone treatment: a case report. J Clin Psychopharmacol. 2011;31:671–3.
102. Tsuchiyama N, Ando H, Ota T, Sakurai M, Takamura T. Modulating effects of olanzapine on the development of diabetic ketoacidosis. Diabet Med. 2004;21:300–1.
103. Baptista T, Lacruz A, de Mendoza S, Mendoza Guillen JM, Silvera R, Angeles F, et al. Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. Pharmacopsychiatry. 2000;33:81–8.
104. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signalling cascade. Diabetes. 1999;48:1270–4.
105. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry. 1998;44:778–83.
106. American Diabetes Association. Position statement: standards of medical care in diabetes. Diabetes Care. 2011;34:S11–61.
107. Rubin RR, Ma Y, Marrero DG, Peyrot M, Barrett-Connor EL, Kahn SE, et al. Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the Diabetes Prevention Program. Diabetes Care. 2008;31:420–6.
108. Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry. 2009;166:591–8.
109. Derijks HJ, Meyboom RH, Heerdink ER, De Koning FH, Janknegt R, Lindquist M, et al. The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports. Eur J Clin Pharmacol. 2008;64:531–8.
110. Kivimäki M, Batty GD, Jokela M, Ebmeier KP, Vahtera J, Virtanen M, et al. Antidepressant medication use and risk of hyperglycemia and diabetes mellitus: a noncausal association? Biol Psychiatry. 2011;70:978–84.
111. Khoza S, Barner JC. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports. Int J Clin Pharm. 2011;33:484–92.
112. Aronne LJ, Segal KR. Weight gain in the treatment of mood disorders. J Clin Psychiatry. 2003;64:22–9.
113. Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care. 2000;23:618–23.
114. Maheux P, Ducros F, Bourque J, Garon J, Chiasson JL. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord. 1997;21:97–102.
115. Lustman PJ, Clouse RE, Nix BD, Freedland KE, Rubin EH, McGill JB, et al. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry. 2006;63:521–9.
116. Demyttenaere K, Jaspers L. Review: bupropion and SSRI-induced side effects. Psychopharmacology. 2008;22:792–804.
117. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602.
118. Tollefson G, Lesar T. Nonketotic hyperglycemia associated with loxapine and amoxapine: case report. J Clin Psychiatry. 1983;44:347–8.
119. Danenberg HD. Salbutamol intoxication. Harefuah. 1997;132:549–51.
120. Thomas DJ, Gill B, Brown P, Stubbs WA. Salbutamol-induced diabetic ketoacidosis. Br Med J. 1977;2(6084):438.
121. Moustafa F, Garrouste C, Bertrand PM, Kauffmann S, Schmidt J. Lactic acidosis after inhaled beta-2 agonists: about 2 cases. Ann Fr Anesth Reanim. 2014;33:49–51.
122. Chapman MG. Salbutamol-induced acidosis in pregnant diabetics. Br Med J. 1977;1(6061):639–40.
123. Dawson KP, Penna AC, Manglick P. Acute asthma, salbutamol and hyperglycaemia. Acta Paediatr. 1995;84(3):305–7.
124. Koh YI, Choi IS. Lactic acidosis associated with the usual theophylline dose in a patient with asthma. Korean J Intern Med. 2002;17(2):147–9.
125. Higbee MD, Kumar M, Galant SP. Stimulation of endogenous catecholamine release by theophylline: a proposed additional mechanism of action for theophylline effects. J Allergy Clin Immunol. 1982;70:377–82.
126. Kearney TE, Manoguerra AS, Curtis GP, Ziegler MG. Theophylline toxicity and the beta-adrenergic system. Ann Intern Med. 1985;102:766–9.
127. Shannon M, Lovejoy FH. The influence of age vs peak serum concentration on life-threatening events after chronic theophylline intoxication. Arch Intern Med. 1990;150:2045–8.
128. Yang JY, Cui XL, He XJ. Non-ketotic hyperosmolar coma complicating steroid treatment in childhood nephrosis. Pediatr Nephrol. 1995;9(5):621–2.
129. Jensen K, Steinthorsdottir KJ, Brandt B. In-hospital cardiac arrest due to unobserved steroid-induced hyperglycaemic hyperosmolar syndrome. Ugeskr Laeger. 2013;175(15):1044–5.
130. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract. 2009;15:469–74.
131. Dhikav V, Anand KS. Inhaled steroids: hyperglycaemia—a side effect. J Indian Acad Clin Med. 2011;2:149.
132. Kallock E, Neher JO, Safranek S. Clinical inquiries. Do intra-articular steroid injections affect glycemic control in patients with diabetes? J Fam Pract. 2010;59:709–10.
133. Fleming P, Drazek L, Shaw JC. Hyperglycemia following intralesional corticosteroid injection in a patient with type I diabetes mellitus. J Cutan Med Surg. 2014;18:275–6.
134. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154:97–101.
135. Delaunay F, Khan A, Cintra A, Davani B, Ling ZC, Andersson A, et al. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Investig. 1997;100:2094–8.
136. Crouthamel MC, Kahana JA, Korenchuk S, Zhang SY, Sundaresan G, Eberwein DJ, et al. Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res. 2009;15(1):217–25.
137. Hershey DS, Bryant AL, Olausson J, Davis ED, Brady VJ, Hammer M. Hyperglycemic-inducing neoadjuvant agents used in treatment of solid tumors: a review of the literature. Oncol Nurs Forum. 2014;41:E343–54.
138. Derr RL, Ye X, Islas MU, Desideri S, Saudek CD, Grossman SA. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009;27(7):1082–6.
139. Haas NB, Quirt I, Hotte S, McWhirter E, Polintan R, Litwin S, et al. Phase II trial of vorinostat in advanced melanoma. Investig New Drugs. 2014;32(3):526–34.
140. Benton CB, Thomas DA, Yang H, Ravandi F, Rytting M, O’Brien S, et al. Safety and clinical activity of 5-aza-2′-deoxycytidine (decitabine) with or without hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014;167:356–65.
141. Ciombor KK, Feng Y, Benson AB 3rd, Su Y, Horton L, Short SP, et al. Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group. Investig New Drugs. 2014;32:1017–27.
142. Atlan-Gepner C, Bouabdallah R, Valero R, Coso D, Vialettes B. A cyclophosphamide-induced autoimmune diabetes. Lancet. 1998;352(9125):373–4.
143. Spinola-Castro AM, Siviero-Miachon AA, Andreoni S, Tosta-Hernandez PD, Macedo CR, Lee ML. Transient hyperglycemia during childhood acute lymphocytic leukemia chemotherapy: an old event revisited. Clin Adv Hematol Oncol. 2009;7(7):465–72.
144. Mondal R, Nandi M, Tiwari A, Chakravorti S. Diabetic ketoacidosis with L-asparaginase therapy. Indian Pediatr. 2011;48(9):735–6.
145. Roberson JR, Raju S, Shelso J, Pui CH, Howard SC. Diabetic ketoacidosis during therapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50(6):1207–12.
146. Hsu YJ, Chen YC, Ho CL, Kao WY, Chao TY. Diabetic ketoacidosis and persistent hyperglycemia as long-term complications of L-asparaginase-induced pancreatitis. Zhonghua Yi Xue Za Zhi (Taipei). 2002;65(9):441–5.
147. Penfornis A, Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabetes Metab. 2006;32:539–46.
148. Boots JM, van Duijnhoven EM, Christiaans MH, Wolffenbuttel BH, van Hooff JP. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol. 2002;13:221–7.
149. Marchetti P, Vincenti F, Friman S. New-onset diabetes imapaired fasting glucose after renal transplantation: results of a prospective, randomised trial comparing cyclosporine versus tacrolimus. Diabetologia. 2006;49:500.
150. Bäckman LA. Post-transplant diabetes mellitus: the last 10 years with tacrolimus. Nephrol Dial Transplant. 2004;19:13–6.
151. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol. 2005;16:3128–35.
152. Gonwa T, Mendez R, Yang HC, Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation. 2005;75:1213–20.
153. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol. 1996;25:283–91.
154. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol. 1996;24:38–47.
155. Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther. 2003;18:549–58.
156. Panetta JD, Gilani N. Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2009;30:597–602.
157. Yamazaki M, Sato A, Takeda T, Komatsu M. Distinct clinical courses in type 1 diabetes mellitus induced by peg-interferon-alpha treatment for chronic hepatitis C. Intern Med. 2010;49(5):403–7.
158. Shiba T, Higashi N, Nishimura Y. Hyperglycaemia due to insulin resistance caused by interferon-gamma. Diabet Med. 1998;15:435–6.
159. Wu JJ, Tsai TF. Recurrent hyperglycemia during adalimumab treatment in a patient with psoriasis. Arch Dermatol. 2008;144(10):1403–4.
160. Crook D, Godsland I. Safety evaluation of modern oral contraceptives: effects on lipoprotein and carbohydrate metabolism. Contraception. 1998;57:189–201.
161. Friedrich A, Ludwig AK, Jauch-Chara K, Loebig M, Rudolf S, Tauchert S, et al. Oral contraception enhances growth hormone responsiveness to hyper- and hypoglycaemia. Diabet Med. 2012;29(3):345–50.
162. Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev. 2014;4:CD006133.
163. Reed ML, Merriam GR, Kargi AY. Adult growth hormone deficiency—benefits, side effects, and risks of growth hormone replacement. Front Endocrinol (Lausanne). 2013;4:64.
164. Dominici FP, Turyn D. Growth hormone-induced alterations in the insulin-signaling system. Exp Biol Med (Maywood). 2002;227:149–57.
165. Garg AK. Hyperglycemia during replacement growth hormone therapy. J Pediatr. 1994;125:329.
166. Johannsson G, Rosén T, Bengtsson B. Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin Endocrinol (Oxf). 1997;47:571–81.
167. Hoffman A, Kuntze JE, Baptista J, Baum HB, Baumann GP, Biller BM, et al. Growth hormone replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:204–56.
168. Hwang IT. Efficacy and safety of growth hormone treatment for children born small for gestational age. Korean J Pediatr. 2014;57(9):379–83.
169. Batra YK, Rajeev S, Samra T, Rao KL. Octreotide-induced severe paradoxical hyperglycemia and bradycardia during subtotal pancreatectomy for congenital hyperinsulinism in an infant. Paediatr Anaesth. 2007;17(11):1117–9.
170. Samson SL. Long-term medical treatment of Cushing’s disease with pasireotide: a review of current evidence and clinical experience. Exp Clin Endocrinol Diabetes. 2014;122(8):445–50.
171. Singh PK, Kumar P. Acitretin induced reversible hyperglycemia. Indian J Dermatol Venereol Leprol. 2004;70(3):183.
172. Pathak RD, Jayaraj K, Blonde L. Thalidomide-associated hyperglycemia and diabetes: case report and review of literature. Diabetes Care. 2003;26(4):1322–3.
173. Blanco-Coronado JL, Repetto M, Ginestal RJ, Vicente JR, Yelamos F, Lardelli A. Acute intoxication by endosulfan. J Toxicol Clin Toxicol. 1992;30(4):575–83.
174. Polo-Garvín A, García-Sánchez MJ, Perán F, Almazán A. Evaluation of the hemodynamic and endocrino-metabolic response to tracheal intubation in patients anesthetized with thiopental or propofol. Rev Esp Anestesiol Reanim. 1993;40(6):344–8.
175. Hirai M, Yasuhi I, Ishimaru T, Yamabe T, Kubota K. Effect of prolonged intravenous ritodrine tocolysis on diurnal glucose profiles in pregnant women with normal carbohydrate tolerance. Nihon Sanka Fujinka Gakkai Zasshi. 1996;48(7):488–94.
176. Jain P, Girardi LS, Sherman L, Berelowicz M, Smith LG. Insulin resistance and development of diabetes mellitus associated with megestrol acetate therapy. Postgrad Med J. 1996;72(848):365–7.
177. Tkach JR. Indomethacin-induced hyperglycemia in psoriatic arthritis. J Am Acad Dermatol. 1982;7(6):802–3.
178. Gattereau A, Bielmann P, Durivage J, Davignon J, Larochelle P. Effect of acute and chronic administration of calcitonin on serum glucose in patients with Paget’s disease of bone. J Clin Endocrinol Metab. 1980;51(2):354–7.
179. Mimouni-Bloch A, Mimouni M. Clonidine-induced hyperglycemia in a young diabetic girl. Ann Pharmacother. 1993;27(7–8):980.
180. Mandal AK, Hiebert LM. Is diuretic-induced hyperglycemia reversible and inconsequential? J Diabetes Res Clin Metab. 2012;1:1–5.
181. Cohen MH, Nihill MR. Postoperative ketotic hyperglycaemia during prostaglandin E infusion in infancy. Pediatrics. 1983;71:842–4.
182. Adams ME. Hype about glucosamine. Lancet. 1999;354:353–4.
183. Kurz M. Diamox and manifestation of diabetes mellitus. Wien Med Wochenschr. 1968;118(11):239–41.
184. Ipp E, Schusdziarra V, Harris V, Unger RH. Morphine-induced hyperglycemia: role of insulin and glucagon. Endocrinology. 1980;107(2):461–3.
185. Cowley AJ, Elkeles RS. Diabetes and therapy with potent diuretics. Lancet. 1978;1:154.
186. Korenyi C, Lowenstein B. Chlorpromazine induced diabetes. Dis Nerv Syst. 1968;29(12):827–8.